Back to Search
Start Over
CCTA to Routinely Guide Invasive Management in Patients With CABG: Over-Testing or Essential?
- Source :
-
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2024 Sep; Vol. 17 (9), pp. e014605. Date of Electronic Publication: 2024 Sep 17. - Publication Year :
- 2024
-
Abstract
- Competing Interests: Dr Berry is employed by the University of Glasgow, which holds consultancy and research agreements with companies that have interests in the management of angina. The companies include Abbott Vascular, AstraZeneca, Auxilius Pharma, Boehringer Ingelheim, CorFlow, Coroventis, HeartFlow, Siemens Healthcare, Therox, and Valo Health. The other authors report no conflicts.
- Subjects :
- Humans
Predictive Value of Tests
Computed Tomography Angiography
Clinical Decision-Making
Coronary Angiography
Risk Factors
Treatment Outcome
Patient Selection
Unnecessary Procedures
Percutaneous Coronary Intervention adverse effects
Coronary Artery Bypass adverse effects
Coronary Artery Disease therapy
Coronary Artery Disease diagnostic imaging
Coronary Artery Disease surgery
Subjects
Details
- Language :
- English
- ISSN :
- 1941-7632
- Volume :
- 17
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Circulation. Cardiovascular interventions
- Publication Type :
- Academic Journal
- Accession number :
- 39286900
- Full Text :
- https://doi.org/10.1161/CIRCINTERVENTIONS.124.014605